ElenbeceSTAT 是一种高效、有口服活性的，能透过 CNS 的BACE-1抑制剂，它有用于阿尔茨海默病 (AD) 的研究潜力。

Elenbecestat is an effective oral bioutilization and CNS penetrating ACE-1 inhibitor for the treatment of Alzheimer's disease.

E2609 has been shown to reduce Ab production in the plasma, brain, and cerebrospinal fluid (CSF) of rodents.E2609 is a potent BACE1 inhibitor with an IC50 of ~7 nmol/L in cell-based assay.

E2609 (0.3-30 mg/kg; p.o.) potently inhibits Ab1-40 and Ab1-42 production in the plasma and CSF of non-human primates.E2609 displays the plasma half-life of 12-16 hours after once daily dosing.

1388651-30-6

C19H18F3N5O2S

437.44

E2609

DMSO:250 mg/mL (571.51 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years